Showing 15 posts of 17 posts found.

NICE recommends Hepcludex for NHS use to treat aggressive form of viral hepatitis

May 15, 2023
Medical Communications NHS, NICE, Virology, hepatitis

The National Institute for Health and Care Excellence (NICE) has recommended Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta …


AbbVie’s Mavyret scores FDA label expansion to shorten treatment duration for hepatitis C patients

September 27, 2019
Medical Communications, Sales and Marketing AbbVie, FDA, hepatitis, hepatitis C, mavyret, pharma

The FDA has chosen to expand the existing label for AbbVie’s Mavyret (glecaprevir/pibrentasvir), it has been revealed, to include the …


AbbVie sue NHS over hepatitis C drug procurement

November 8, 2018
Business Services AbbVie, NHS, britain, court, hep C, hepatitis, ruling

American pharma firm AbbVie are suing Britain’s NHS after claiming that the health service’s procurement of hepatitis C drugs breached …


Nine in 10 people unaware they have hepatitis

July 28, 2017
Medical Communications, Research and Development Gilead, biotech, drugs, hepatitis, hepatitis C, pharma, pharmaceutical

The WHO has released a report on the state of hepatitis prevention and treatment to mark World Hepatitis Day, with …


Gilead’s Sovaldi gets Indian patent; critics call it “major blow” to patient access

May 11, 2016
Manufacturing and Production, Research and Development, Sales and Marketing India, harm, hepatitis, patent, patient access, sovaldi

Gilead has been granted a patent for its hepatitis C drug, Sovaldi (sofosbuvir), in India which has sparked dismay among …


Gilead presents data highlighting progress and efficacy in liver and hepatitis C therapies

April 20, 2016
Research and Development, Sales and Marketing Gilead, harvoni, hepatitis, liver, sofosbuvir

Gilead (NASDAQ: GILD) has presented a broad range of results on its current and potential therapeutics at the International Liver …


AbbVie announces positive Phase III results in hepatitis C drug

April 14, 2016
Manufacturing and Production, Research and Development AbbVie, hepatitis, phase III

AbbVie (NYSE: ABBV) has announced positive results from their Phase III evaluating the combination of Viekirax and Exviera, with or …


Medicines Patent Pool to include hep C and TB drugs

November 9, 2015
Sales and Marketing Medicines Patent Pool, affordable drugs, hep C, hepatitis, hepatitis C, medicines access, tuberculosis

The Medicines Patent Pool has expanded to include a mandate to make treatments for hepatitis C and tuberculosis affordable and …

Sovaldi image

Gilead frustrated despite final NICE Sovaldi nod

February 25, 2015
Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, sofosbuvir, sovaldi

NICE has published final guidance confirming its approval of Gilead’s controversial blockbuster hepatitis C treatment Sovaldi – but Gilead and …

Olysio  image

Janssen privy to new pricing scheme and see NICE nod

January 16, 2015
Sales and Marketing Janssen, NHS, NICE, hep C, hepatitis, olysio, ribavirin, simeprevir

Janssen’s hepatitis C drug Olysio has been approved by NICE whilst also reaching a novel ‘pay if you clear’ pricing …

Sovaldi image

NICE approves Sovaldi

January 16, 2015
Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, pharma, sofosbuvir, sovaldi

NICE has recommended Sovaldi in final draft guidance and extended its scope, despite concerns over the price of the blockbuster …


Abbvie Hep C drug gains FDA approval

December 22, 2014
Sales and Marketing AbbVie, FDA, Gilead, Viekira Pak, dasabuvir, harvoni, hepatitis, hepatits C

Abbvie has gained sign-off for its rival treatment to challenge Gilead’s dominance of the growing market for new hepatitis C …

J&J hepatitis C drug begins phase III trials

February 23, 2011
Research and Development J&J, JJ, Johnson and Johnson, TMC435, Tibotec, hepatitis, hepatitis C

Johnson & Johnson has begun late stage trials of hepatitis C drug TMC435 as a first line treatment for the …

Novartis drops two drug candidates, takes $600 million hit

October 6, 2010
Research and Development Human Genome Sciences, Novartis, candidiasis, hepatitis

Novartis will incur a charge of nearly $600 million after it halted development of investigational drugs for hepatitis C and …


BMS to acquire ZymoGenetics

September 8, 2010
Research and Development, Sales and Marketing BMS, hepatitis

 Bristol-Myers Squibb is to acquire biopharma company ZymoGenetics for $885 million to add to its ‘string of pearls’of small biotech …

Latest content